Pharma industry 'strategic crisis'


The pharma industry is grappling with a ‘strategic crisis’ according to three quarters of companies surveyed in a report from consultancy firm Roland Berger. The problem is shrinking margins, caused by price and cost pressure, regulatory change and expiring patents.

The top 10 pharma companies increased sales by 13% from 2009 to 2010, but their profits dropped during the same period by 4%. Compounding the problem in the long term, R&D costs have risen 80% over the past 10 years, while the number of new product launches has dropped by 43%.

Emerging markets offer the biggest growth – their market share is set to rise to 40% by 2016. The market for pharmaceutical products will grow on average by 4.5% annually until 2016. But growth in emerging markets will increase by almost 12%. China, Brazil, India and Russia (the so-called BRIC economies) in particular are experiencing high growth.

Half of the companies said they would be willing to move their administration, R&D and sales departments to emerging market regions.


Related Content

Weathering the storm

6 January 2014 Business

news image

Pharmaceutical industry roundup 2013

The hunt for innovation

31 January 2014 Premium contentFeature

news image

Big pharma companies are embracing a more open and collaborative approach. Nuala Moran discovers who’s working with whom

Most Read

Refining Avogadro’s number on way to new kilo

21 July 2015 Research

news image

Most precise value yet reduces uncertainty down to 20 atoms in a billion

Weaving is believing

23 July 2015 The Crucible

news image

Philip Ball unpicks the history of science’s woollen wardrobe

Most Commented

Caramel colour in soft drinks linked to cancer

26 February 2015 News and Analysis

news image

Regulatory bodies and researchers sceptical of study on 4-MEI found in food colour

Weaving is believing

23 July 2015 The Crucible

news image

Philip Ball unpicks the history of science’s woollen wardrobe